{"filing":{"accession_number":"0001140361-26-031058","cik":"0001133416","ticker":"GALT","company_name":"GALECTIN THERAPEUTICS INC","form":"8-K","filing_date":"2026-08-04","report_date":"2026-07-31","primary_document":"ef20079045_8-k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1133416/000114036126031058/ef20079045_8-k.htm"},"events":[{"id":23848,"run_id":21570,"accession_number":"0001140361-26-031058","anchor_item_number":"3.02","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"summary":"This Item 3.02 discloses the issuance of 34,376,167 shares of common stock to the Company's Chairman upon conversion of $105.8 million in convertible promissory notes. Although technically exempt from registration under Section 3(a)(9) as an exchange with an existing security holder, this represents a substantial dilutive equity issuance that materially increases share count (from ~66.5M to ~100.8M shares, a 52% increase) and significantly increases the Chairman's ownership stake to 44.3% of voting power. The conversion eliminates substantial debt but creates substantial dilution to existing shareholders.","company_name":"GALECTIN THERAPEUTICS INC","ticker":"GALT","filing_date":"2026-08-04","form":"8-K","submitted_at":null,"items":[{"id":24195,"accession_number":"0001140361-26-031058","item_number":"3.02","item_title":null,"event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"This Item 3.02 discloses the issuance of 34,376,167 shares of common stock to the Company's Chairman upon conversion of $105.8 million in convertible promissory notes. Although technically exempt from registration under Section 3(a)(9) as an exchange with an existing security holder, this represents a substantial dilutive equity issuance that materially increases share count (from ~66.5M to ~100.8M shares, a 52% increase) and significantly increases the Chairman's ownership stake to 44.3% of voting power. The conversion eliminates substantial debt but creates substantial dilution to existing shareholders.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-05T02:22:10.702677+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":24195,"accession_number":"0001140361-26-031058","item_number":"3.02","item_title":null,"event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"This Item 3.02 discloses the issuance of 34,376,167 shares of common stock to the Company's Chairman upon conversion of $105.8 million in convertible promissory notes. Although technically exempt from registration under Section 3(a)(9) as an exchange with an existing security holder, this represents a substantial dilutive equity issuance that materially increases share count (from ~66.5M to ~100.8M shares, a 52% increase) and significantly increases the Chairman's ownership stake to 44.3% of voting power. The conversion eliminates substantial debt but creates substantial dilution to existing shareholders.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-05T02:22:10.702677+00:00","company_name":"GALECTIN THERAPEUTICS INC","ticker":"GALT","filing_date":"2026-08-04"}]}